Bayer to acquire Conceptus

Published: 29-Apr-2013

Broadening its contraception portfolio


Bayer has agreed to buy US birth control devices company Conceptus for US$1.1bn (€852m) to complement the German company’s offerings in women’s health.

Conceptus is the developer of the Essure procedure, a non-surgical permanent birth control method, which is sold in the US and other countries.

With this acquisition, Bayer says it will be able to offer a complete range of short-term, long-term and permanent contraceptive choices for women.

Within the next 10 business days, Bayer will launch a public tender offer to acquire all shares in Conceptus. The deal should be completed by June.

‘The acquisition of Conceptus represents an excellent fit for our HealthCare business – specifically in the US, the world's most important healthcare market,’ said Marijn Dekkers, CEO of Bayer.

The acquisition of Conceptus represents an excellent fit for our HealthCare business

Andreas Fibig, President of Bayer HealthCare Pharmaceuticals, added: ‘Essure completes Bayer's portfolio of long-acting intrauterine systems and short-acting oral contraceptives. Our experience in the field of gynaecology combined with our sales and distribution expertise will help to further develop Conceptus' business.’

Keith Grossman, President and CEO of Conceptus, said: ‘We believe that under Bayer's ownership the Essure product will more rapidly become the standard of care in our established markets, and will benefit in new markets from Bayer's global presence.’

Conceptus reported net sales of $141m (€110m) in 2012. Adjusted EBITDA for 2012 was $28.2m (€22m). Headquartered in Mountain View, California, the company employs around 300 people.

You may also like